Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 23;4(2):bjgpopen20X101069.
doi: 10.3399/bjgpopen20X101069. Print 2020.

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review

Kome Gbinigie  1 , Kerstin Frie  2
Affiliations

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review

Kome Gbinigie et al. BJGP Open. .

Abstract

Background: On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease.

Aim: To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.

Design & setting: A rapid review of the literature was conducted.

Method: Electronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020.

Results: There is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (n = 30 and n = 36) and suffer methodological limitations. No medium or long-term follow-up data is available.

Conclusion: At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.

Keywords: COVID-19; Chloroquine; Hydroxychloroquine; coronavirus; general practice; primary healthcare.

PubMed Disclaimer

References

    1. Worldometer Total Coronavirus Cases in the United Kingdom. https://www.worldometers.info/coronavirus/country/uk/ 2020 6 Apr 2020.
    1. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa237. - DOI - PMC - PubMed
    1. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949:105949. doi: 10.1016/j.ijantimicag.2020.105949. - DOI - PMC - PubMed
    1. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;105945 - PMC - PubMed
    1. Chauhan A, Tikoo A, AJHm T. The enigma of the clandestine association between chloroquine and HIV-1 infection. HIV Med. 2015;16(10):585–590. doi: 10.1111/hiv.12295. - DOI - PubMed

LinkOut - more resources